Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes - Poll - MDSpire

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

  • By

  • Amer M. Zeidan

  • Valeria Santini

  • María Díez-Campelo

  • Michael R. Savona

  • Mikkael A. Sekeres

  • Yazan F. Madanat

  • Pierre Fenaux

  • Azra Raza

  • Moshe Mittelman

  • Sylvain Thépot

  • Rena Buckstein

  • Ulrich Germing

  • David Valcárcel

  • Anna Jonášová

  • Sheetal Shah

  • Qi Xia

  • Libo Sun

  • Shyamala Navada

  • Tymara Berry

  • Uwe Platzbecker

  • Rami S. Komrokji

  • April 7, 2026

  • 0 min

Share

Original Source(s)

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

  • by Amer M. Zeidan, Valeria Santini, María Díez-Campelo, Michael R. Savona, Mikkael A. Sekeres, Yazan F. Madanat, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, David Valcárcel, Anna Jonášová, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Tymara Berry, Uwe Platzbecker, Rami S. Komrokji

  • April 7, 2026

Related Content

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

Association Between Iron Deficiency and Dementia Risk: Insights from the AMORIS Population-Based Study in Sweden

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons